Watch Video Now Icon WATCH NOW: Clinical experience with ALPROLIX

We are committed to supporting you and your patients

Information and resources for your practice

Protection,* Experience,
 and Dosing:
A Discussion With Dr De Angulo


Calculate your patient's dose by weight for prophylaxis, bleed control, or surgery.

Billing and
 coding information

The codes listed below are provided for informational purposes only and are not intended to substitute for or influence the independent medical judgment of the prescriber. The codes may not apply to all patients or to all health plans, and additional codes not listed may apply to some patients. The treating physician is solely responsible for diagnosis, coding and determination of the appropriate ICD-10-CM codes that describe the patient's condition and are supported by the medical record.

The ICD-10-CM and HCPCS codes provided are based on AMA or CMS guidelines. Use of the information below does not guarantee that the payor will provide coverage for ALPROLIX. Because government and other third-party payor coding requirements change periodically, please verify current coding requirements directly with the payor being billed.

Resources for your patients

Instructions for UseDownload icon

This document contains information on how to use ALPROLIX, including reconstitution, pooling, administration, and storage.

ALPROLIX offers a range of financial assistance programs for your patients

Access to these and other services is voluntary, and your patients are not obligated to begin treatment if they contact us. You and your patients make all treatment-related decisions.

Free Trial Plus Program

Patients can receive their first 30-day supply of ALPROLIX generally within 24-48 hours with a valid prescription from their healthcare provider. Sanofi Patient Services will review your patient's health insurance information for their coverage of ALPROLIX while you and your patient decide if this is the right medication for them to continue taking.

Copay Program

Whether your patient is new to ALPROLIX or already on therapy, ALPROLIX offers a Copay Program to eligible patients that can cover up to $20,000 of copayment, or co-insurance, and out-of-pocket costs associated with their prescription. Best of all, there are no income requirements or caps, so your patient can get started with their treatment right away.

Factor Access Program

Helps your patient access ALPROLIX, even if their insurance coverage is interrupted—for example, they are between jobs or changing insurers.

Sanofi Support Programs Enrollment Form
Sanofi Support Programs Enrollment Form in Spanish (en Español)
Sanofi Support Programs Bilingual Enrollment Form

Not valid where prohibited by law. Sanofi reserves the right to modify or discontinue the programs at any time. Program details provided upon registration. Free Trial Plus and Copay Program not valid for prescriptions covered by or submitted for reimbursement under Medicare, Medicaid, VA, DoD, TRICARE®, or similar federal or state programs including any state pharmaceutical assistance programs. Copay program savings may vary depending on patients’ out-of-pocket costs.

Patients can manage their hemophilia with the help of MicroHealth tracking

Sanofi has joined with MicroHealth in supporting patients and healthcare providers to better manage hemophilia.

Learn more

Hand holding heart icon

Hemophilia B Advocacy Groups

This listing is provided as a resource only and does not constitute an endorsement by Sanofi of any particular organization or its programming. Additional resources on this topic may be available and should be investigated. Sanofi does not review or control the content of non-Sanofi websites. These listings do not constitute an endorsement by Sanofi of information provided by any other organizations.

The Coalition for Hemophilia B

National Hemophilia Foundation

Hemophilia Federation of America

World Federation of Hemophilia




  • ALPROLIX is contraindicated in patients who have a known history of hypersensitivity reactions, including anaphylaxis, to the product or its excipients.


  • Allergic-type hypersensitivity reactions, including anaphylaxis, are possible with factor replacement therapies, and have been reported with ALPROLIX. Discontinue use of ALPROLIX if hypersensitivity symptoms occur, and initiate appropriate treatment.
  • Formation of neutralizing antibodies (inhibitors) to Factor IX has been reported following administration of ALPROLIX. Patients using ALPROLIX should be monitored for the development of Factor IX inhibitors. Clotting assays (e.g., one-stage) may be used to confirm that adequate Factor IX levels have been achieved and maintained.
  • The use of Factor IX products has been associated with the development of thromboembolic complications.
  • Nephrotic syndrome has been reported following attempted immune tolerance induction in hemophilia B patients with Factor IX inhibitors and a history of allergic reactions to Factor IX. The safety and efficacy of using ALPROLIX for immune tolerance induction have not been established.


  • The most common adverse reactions (incidence ≥1%) in previously untreated patients were injection site erythema, hypersensitivity, and Factor IX inhibition. The most common adverse reactions (incidence ≥1%) in previously treated patients were headache, oral paresthesia, and obstructive uropathy.


ALPROLIX® is a recombinant DNA derived, coagulation Factor IX concentrate indicated in adults and children with hemophilia B for:

  • On-demand treatment and control of bleeding episodes
  • Perioperative management of bleeding
  • Routine prophylaxis to reduce the frequency of bleeding episodes

Limitation of Use
ALPROLIX is not indicated for induction of immune tolerance in patients with hemophilia B.

Click here to learn more about Sanofi's commitment to fighting counterfeit drugs.